Welcome to our dedicated page for Anaptysbio SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AnaptysBio, Inc. filings document the company’s transition to a royalty management business and its Nasdaq-listed common stock under the symbol ANAB. Recent Form 8-K and 8-K/A filings cover the completed separation of First Tracks Biotherapeutics, related separation and transition services agreements, pro forma financial information, and material-event reporting tied to the new corporate structure.
The filing record also includes disclosures on operating and financial results, Regulation FD materials, stock repurchase authorizations, governance matters, and contract litigation involving the Jemperli Collaboration and Exclusive License Agreement. These documents frame AnaptysBio’s capital structure, collaboration rights, royalty-related business focus, and public-company reporting obligations.
Notice of proposed sale by an insider of common stock. The filing lists 850 common shares to be sold on 06/17/2026 pursuant to a stock option exercise for cash, routed through Morgan Stanley Smith Barney LLC. The excerpt also records numerous prior dispositions by Dennis Mulroy between 05/15/2026 and 06/16/2026, including a 35,000-share sale on 06/11/2026. These entries show transaction dates, share counts, and gross proceeds for each sale.
ANAPTYSBIO director John P. Schmid exercised restricted stock units into common shares. On June 15, 2026 he converted 6,030 RSUs into 6,030 shares of common stock for no cash consideration. Following the transaction, he holds 37,652 common shares directly, with no remaining RSU position reported.
AnaptysBio director Renton Hollings reported a routine equity compensation event. On June 15, 2026, he exercised 6,030 restricted stock units (RSUs), receiving 6,030 shares of common stock for no cash consideration, as each RSU converts into one share upon settlement.
Following this RSU settlement, Hollings directly holds 10,995 shares of AnaptysBio common stock. The RSU award vested 100% on June 15, 2026, conditioned on continued service through the vesting date, so this transaction reflects compensation vesting rather than an open‑market purchase or sale.
ANAPTYSBIO director John A. Orwin exercised restricted stock units into common shares. On June 15, 2026, he converted 6,030 restricted stock units into 6,030 shares of common stock at no cash cost, increasing his directly held stake to 16,695 shares.
Each RSU represents a right to receive one share of common stock upon settlement. The RSU award was structured to vest 100% on June 15, 2026, contingent on Mr. Orwin’s continued service to the company through that date. The filing reports no share sales, tax withholding, or gifts in connection with this transaction.
ANAB notice of proposed sale: the filing lists multiple planned sales of Common shares by Dennis Mulroy via stock option exercise and open-market dispositions with specific trade dates and share counts. The excerpt catalogs individual sales from 05/15/2026 through 06/16/2026, including multiple daily transactions and cash settlements.
The entries show per-trade share quantities and gross sale amounts for each date, identifying Morgan Stanley Smith Barney LLC as the executing broker. The filing is a routine resale disclosure under the securities rules for orderly disposition.
Company: ANAB. This Form 144 notice lists a proposed sale of 20,000 shares of Common Stock via a stock option exercise for cash, dated 06/15/2026. The filing also lists numerous recent dispositions by Dennis Mulroy on multiple dates in May–June 2026, with individual sale sizes shown per date and dollar amounts.
ANAB affiliate filed a Form 144 proposing sales of Common Stock. The notice lists multiple proposed dispositions by Dennis Mulroy, including individual sales dated 05/15/2026 through 06/12/2026. The filing shows specific trade dates, share counts, and gross proceeds for each listed sale.
ANAB notice of proposed sale: Morgan Stanley Smith Barney LLC intends to sell 35,000 shares of Common Stock on 06/11/2026 via a stock option exercise for $1,848,750.00 in cash. The filing also lists multiple recent open-market dispositions by Dennis Mulroy between 05/15/2026 and 06/10/2026, including several sales of 10,000–22,987 shares with disclosed gross proceeds per trade.
ANAB affiliate filed a Form 144 disclosing multiple proposed and completed dispositions of Common Stock. The filing lists a 06/10/2026 stock option exercise of 20,000 shares (cash exercise) and a series of sales between 05/15/2026 and 06/09/2026 with individual share quantities and gross proceeds shown. The entries name Dennis Mulroy as the selling party and report per-trade proceeds in dollars alongside each share count.
ANAB: Notice of proposed sale of 20,000 shares of Common Stock via a stock option exercise on 06/09/2026, with cash proceeds indicated to the issuer. The filing lists multiple recent disposals by Dennis Mulroy in May–June 2026, including 21,987 shares on 06/08/2026 and 22,491 shares on 06/05/2026.